GlassScriptPhysician profile
Barbara Gredysa
NPI 1457678500
$1,610.68
in general payments reported to CMS, 2019-2025
23 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $276 · 2021: $338 · 2023: $186 · 2024: $84.29 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $242.46 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $168.81 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $147.33 | 2019-2023 | Mounjaro |
| Amgen INC. | $140.66 | 2019-2025 | Evenity |
| Beta Bionics, INC. | $130.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $112.13 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.85 | 2019-2023 | Synjardy |
| Abbott Laboratories | $95.70 | 2020-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $64.68 | 2019-2021 | |
| Medtronic, INC. | $59.29 | 2021 | |
| Amarin Pharma, INC. | $42.60 | 2020 | |
| Corcept Therapeutics | $40.34 | 2021 | |
| Medtronic Minimed, INC. | $35.15 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $34.22 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $32.03 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $24.39 | 2025 | Tymlos |
| Sanofi Pasteur INC. | $23.36 | 2023 | |
| Rgh Enterprises LLC | $23.11 | 2025 | |
| Dexcom, INC. | $23.09 | 2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $20.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.14 | 2020 | |
| Clarus Therapeutics INC. | $16.12 | 2021 | |
| Ibsa Pharma INC. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Gredysa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.